Machine learning in drug discovery: a review
This review provides the feasible literature on drug discovery through ML tools and
techniques that are enforced in every phase of drug development to accelerate the research …
techniques that are enforced in every phase of drug development to accelerate the research …
Applications of machine learning in drug discovery and development
Drug discovery and development pipelines are long, complex and depend on numerous
factors. Machine learning (ML) approaches provide a set of tools that can improve discovery …
factors. Machine learning (ML) approaches provide a set of tools that can improve discovery …
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma
LJ Costa, S Chhabra, E Medvedova… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …
Artificial intelligence and machine learning in precision and genomic medicine
S Quazi - Medical Oncology, 2022 - Springer
The advancement of precision medicine in medical care has led behind the conventional
symptom-driven treatment process by allowing early risk prediction of disease through …
symptom-driven treatment process by allowing early risk prediction of disease through …
Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
Multiple myeloma (MM) is a neoplastic plasma-cell disorder characterized by clonal
proliferation of malignant plasma cells. Despite extensive research, disease heterogeneity …
proliferation of malignant plasma cells. Despite extensive research, disease heterogeneity …
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
A Palumbo, H Avet-Loiseau, S Oliva… - Journal of clinical …, 2015 - ascopubs.org
Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging …
reliable tool is needed to stratify patients with MM. We combined the International Staging …
Prognostic and predictive biomarker developments in multiple myeloma
CT Wallington-Beddoe, RL Mynott - Journal of hematology & oncology, 2021 - Springer
New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …
decision-making, or prediction, are needed since patients are currently managed in a similar …
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial… - Blood, The Journal …, 2016 - ashpublications.org
Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site
is well-perfused, a rapid dissemination of “fitter” clones may be anticipated. However, an …
is well-perfused, a rapid dissemination of “fitter” clones may be anticipated. However, an …